No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RCUS240517C20000
- 0.10
- -0.09-47.37%
15min DelayTrading May 9 10:32 ET
0.10High0.10Low
0.10Open0.19Pre Close2 Volume27 Open Interest20.00Strike Price20.00Turnover91.27%IV21.84%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.10Time Value100Contract SizeAmericanOptions Type0.0976Delta0.0750Gamma164.96Leverage Ratio-0.0229Theta0.0004Rho16.11Eff Leverage0.0043Vega
Intraday
- 5D
- 1D
News
Earnings Call Summary | Arcus Biosciences(RCUS.US) Q1 2024 Earnings Conference
The following is a summary of the Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript:Financial Performance:Arcus Biosciences reported that they have over $1 billion of cash on hand, which
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $30 Price Target
Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.
Arcus Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 87.5% Wedbush → $30 Reiterates Outperform → Outperform 03/25/2024 212.5% Truist Securities → $5
Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)
Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Arcus Biosciences: Holding Steady Amidst Progress and Uncertainties
Comments
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
The recent sale of Arcus Biosciences shares by the COO and the lack of insider buying over the last year raises caution. The level of insider ownership indicates some alignment between management and smaller shareholders, but it's not particularly high.
1
Despite a moderate P/S ratio, the company's revenue growth lags behind others, potentially problematic if the trend persists. Muted future growth estimates compared to the industry could lead to disappointment if the P/S aligns with the growth outlook.
Arcus Biosciences' cash runway is promising despite a significant drop in revenue. However, shareholders may face costly dilution if the company sells shares to cover another year's operations. The falling revenue is concerning for the cash burning company.
Despite the weaker earnings outlook, the consensus price target suggests analysts do not anticipate a long-term impact on the company’s valuation. However, the downgrade of next year's forecast instills caution regarding Arcus Biosciences' future performance.
Read more